SCHEMBL6792908

SCHEMBL6792908

O=C(/C=C/C=C/c1cccc(C(F)(F)F)c1)N1CCCN(C(=O)/C=C/C=C/c2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.56
ALOX5 P09917 3/20 0.53
MAOB P27338 2/20 0.53
HPGD P15428 4/20 0.52
ALDH1A1 P00352 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
TP53 P04637 3/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
KDM4E B2RXH2 2/20 0.49
CYP3A4 P08684 2/20 0.49
HSD17B10 Q99714 2/20 0.49
NPC1 O15118 1/20 0.49
CTSD P07339 1/20 0.49
ABCB1 P08183 1/20 0.49
GABRA1 P14867 1/20 0.49
MAOA P21397 1/20 0.49
MAPK1 P28482 1/20 0.49
GABRB2 P47870 1/20 0.49
RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6787409 0.84 ALDH1A1 (0.57) LMNAALOX5MAOBHPGDALDH1A1
SCHEMBL6785637 0.80 MEN1 (0.79) LMNAALOX5MAOBHPGDALDH1A1
SCHEMBL10585234 0.78 P4HB (0.56) LMNAMAOBALDH1A1MEN1KMT2A
SCHEMBL6781559 0.78 P4HB (0.56) LMNAMAOBALDH1A1MEN1KMT2A
SCHEMBL6787525 0.78 ALOX5 (0.53) LMNAALOX5MAOBHPGDALDH1A1
SCHEMBL10586039 0.77 LMNA (0.55) LMNAMAOBALDH1A1MEN1KMT2A
SCHEMBL30266639 0.76 ALOX5 (0.69) LMNAALOX5MAOBHPGDALDH1A1
SCHEMBL16598455 0.75 TACR3 (0.64) LMNAHPGDALDH1A1SMN1; SMN2TP53
SCHEMBL16598452 0.75 TACR3 (0.64) LMNAHPGDALDH1A1SMN1; SMN2TP53
SCHEMBL31505202 0.75 LMNA (0.57) LMNAMAOBHPGDALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6828316-B2 Antiallergens KOWA CO., LTD. (JP) 2004-12-07 US disclosed
US-20020042414-A1 Diamide compound and medicine containing the same KOWA CO., LTD. (JP) 2002-04-11 US disclosed
US-6340682-B1 FOR THERAPY OF ALLERGIC IMMUNOLOGICAL DISEASE IS SELECTED FROM ASTHMA, ALLERGIC RHINITIS, INFLAMMATORY LARGE BOWEL DISEASE OR CONTACT DERMATITIS KOWA CO., LTD. (JP) 2002-01-22 US disclosed
EP-0926138-A1 DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME KOWA CO. LTD. (JP) 1999-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042414-A1 Diamide compound and medicine containing the same HRH4, HRH2, HRH1 LMNA 4686/4885ALOX5 819/4885MAOB 868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.